首页> 外文期刊>Infectious Disease Reports >A patient presenting with cholangitis due to Stenotrophomonas maltophilia and Pseudomonas aeruginosa successfully treated with intrabiliary colistine
【24h】

A patient presenting with cholangitis due to Stenotrophomonas maltophilia and Pseudomonas aeruginosa successfully treated with intrabiliary colistine

机译:一例因嗜麦芽窄食单胞菌和铜绿假单胞菌致胆管炎的患者成功接受胆汁内大黄素治疗

获取原文
           

摘要

Anatomical barriers for antibiotic penetration can pose a particular challenge in the clinical setting. Stenotrophomonas maltophilia (SM) and Pseudomonas aeruginosa (PA) are two pathogens capable of developing multiple drug-resistance (MDR) mechanisms. We report the case of a 56-year-old female patient with a permanent percutaneous transhepatic biliary drainage (PTBD), who was admitted to our hospital with a cholangitis due to a MDR Escherichia coli strain. Upon admission, culture-guided antimicrobial therapy was conducted and the biliary catheter was replaced, with poor clinical response. Subsequently, SM and PA were detected. Treatment with fosfomycin and colistine was initiated, again without adequate response. Systemic colistine and tigecycline along with an intrabiliary infusion of colistine for 5 days was then used, followed by parenteral fosfomycin and tigecycline for 7 days. The patient was then successfully discharged. This is the first case report we are aware of on the use of intrabiliary colistine. It describes a new approach to treating cholangitis by MDR bacteria in patients with a PTBD.
机译:抗生素渗透的解剖学障碍在临床环境中可能会带来特殊的挑战。嗜麦芽窄食单胞菌(SM)和铜绿假单胞菌(PA)是能够发展多种耐药(MDR)机制的两种病原体。我们报告了一名56岁的女性患者,该患者永久性经皮经肝胆道引流(PTBD),由于MDR大肠杆菌菌株而因胆管炎入院。入院后,进行了培养指导的抗菌治疗,并更换了胆管,临床反应较差。随后,检测到SM和PA。开始用磷霉素和大黄素进行治疗,再次没有足够的反应。然后使用全身性大肠菌素和替加环素,并在胆汁中进行大肠菌素输注5天,然后进行肠胃外磷霉素和替加环素治疗7天。病人随后成功出院。这是我们了解到的关于胆汁中大肠杆菌的使用的首例病例报告。它描述了一种在PTBD患者中通过MDR细菌治疗胆管炎的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号